Marshall Wace LLP Buys 207,476 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Marshall Wace LLP increased its position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 56.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 576,219 shares of the biopharmaceutical company’s stock after purchasing an additional 207,476 shares during the quarter. Marshall Wace LLP’s holdings in Sangamo Therapeutics were worth $207,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Renaissance Technologies LLC boosted its holdings in shares of Sangamo Therapeutics by 58.8% in the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock valued at $1,479,000 after purchasing an additional 1,528,600 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Sangamo Therapeutics by 4.0% during the 1st quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock worth $3,311,000 after buying an additional 192,385 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its position in shares of Sangamo Therapeutics by 61.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 23,650 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Sangamo Therapeutics in the first quarter valued at about $331,000. Finally, Wasatch Advisors LP raised its stake in Sangamo Therapeutics by 62.4% during the first quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock worth $13,493,000 after acquiring an additional 7,734,400 shares in the last quarter. 56.93% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. StockNews.com began coverage on Sangamo Therapeutics in a research report on Sunday, July 28th. They set a “sell” rating on the stock. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Sangamo Therapeutics in a report on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $2.67.

Sangamo Therapeutics Trading Up 1.4 %

SGMO opened at $0.84 on Friday. The company has a fifty day moving average price of $0.86 and a two-hundred day moving average price of $0.65. Sangamo Therapeutics, Inc. has a 1-year low of $0.29 and a 1-year high of $1.48. The company has a market cap of $174.32 million, a P/E ratio of -0.61 and a beta of 1.23.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The firm had revenue of $0.36 million during the quarter, compared to the consensus estimate of $11.40 million. Sangamo Therapeutics had a negative return on equity of 273.25% and a negative net margin of 2,033.69%. On average, research analysts forecast that Sangamo Therapeutics, Inc. will post -0.47 EPS for the current fiscal year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.